Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib

Anticancer Research

Volumn 29, Issue 7, 2009, Pages 2747-2751

  Shukuya, Takehito ^a   Takahashi, Toshiaki ^a   Tamiya, Akihiro ^a   Ono, Akira ^a   Igawa, Satoshi ^a   Nakamura, Yukiko ^a   Tsuya, Asuka ^a   Murakami, Haruyasu ^a   Naito, Tateaki ^a   Kaira, Kyoichi ^a   Endo, Masahiro ^a   Yamamoto, Nobuyuki ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

EGFR TKI; Gefitinib; Non small cell lung cancer; Paclitaxel; Resistant

Indexed keywords

GEFITINIB; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG RESISTANCE; DRUG SAFETY; DRY SKIN; FATIGUE; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAIL; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; QUINAZOLINES; SURVIVAL ANALYSIS;

EID: 69249170016     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Thatcher N, Chang A, Parikh P et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537, 2005. (Pubitemid 41540110)
2. Kim ES, Hirsh V, Mok T et al: Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809-1818, 2008.
3. Paez JG, Janne PA, Lee JC et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)
4. Lynch TJ, Bell DW, Sordella R et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
5. Pao W and Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol 23: 2556-2568, 2005.
6. Mitsudomi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-1824, 2007.
7. Sequist LV, Bell DW, Lynch TJ et al: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small cell lung cancer. J Clin Oncol 25: 587-595, 2007. (Pubitemid 350002967)
8. Mok T, Wu YL, Thongprasert S et al: Phase III, randomised, open-label, first-line study of gefitinib vs. carboplatin / paclitaxel in clinically selected patients with advanced non-small cell lung cancer (IPASS). Ann Oncol 19: LBA 2, 2008.
9. Takano T, Fukui T, Ohe Y et al: EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 26: 5589-5595, 2008.
10. Schaeybroeck SV, Kyula J, Kelly DM et al: Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther 5: 1154-1165, 2006. (Pubitemid 43881307)
11. Kasahara K, Sone T, Kimura H et al: A phase II trial of weekly paclitaxel (P) and gefitinib (G) in patients (pts) with gefitinib-refractory or -resistant non-small cell lung cancer (NSCLC). J Clin Oncol 22: abst 7091, 2004.
12. Cho BC, Im CK, Park MS et al: Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 25: 2528-2533, 2007. (Pubitemid 47041225)